Pr1E11, a novel anti-TROP-2 antibody isolated by adenovirus-based antibody screening, recognizes a unique epitope

Ikeda, Masahiro; Miki, Yoshio; Kato, Kazunori; Nakamura, Kiminori; Shiina, Sagano; Ichikawa-Ando, Takako; Misaka, Hirofumi; Myojo, Kensuke; Nakamura, Kazuyasu; Sugimoto, Yohei; Hamada, Hirofumi

doi:10.1016/j.bbrc.2015.02.051

Cited by 19 publications

(16 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although several anti-Trop-2 antibodies have been developed, none were amenable to therapeutic use as naked antibodies until Ikeda et al developed Pr1E11. This is an anti-Trop-2 antibody with low internalization activity isolated from Balb/c mice immunized with Pc1 primary human prostate cancer cells, which the group suggested for further investigation in epithelial cancers 42…”

Section: Basic Science Backgroundmentioning

confidence: 99%

<p>Targeting Trop-2 in solid tumors: future prospects</p>

Zaman¹,

Jadid²,

Denson³

et al. 2019

OTT

114

View full text Add to dashboard Cite

Trop-2 is a transmembrane glycoprotein that is upregulated in all cancer types independent of baseline levels of Trop-2 expression. Trop-2 is an ideal candidate for targeted therapeutics due to it being a transmembrane protein with an extracellular domain overexpressed on a wide variety of tumors as well as its upregulated expression relative to normal cells. As a result, several Trop-2-targeted therapeutics have recently been developed for clinical use, such as anti-Trop-2 antibodies and Trop-2-targeted antibody–drug conjugates (ADC). Subsequently, multiple early-phase clinical trials have demonstrated safety and clinical benefit of Trop-2-based ADCs across multiple tumor types. This includes clinical benefit and tolerability in tumor types with limited treatment options, such as triple-negative breast cancer, platinum-resistant urothelial cancer, and small-cell lung cancer. In this review, we elaborate on all clinical trials involving Trop-2.

show abstract

Section: Basic Science Backgroundmentioning

confidence: 99%

<p>Targeting Trop-2 in solid tumors: future prospects</p>

Zaman¹,

Jadid²,

Denson³

et al. 2019

OTT

114

View full text Add to dashboard Cite

show abstract

“…Although several anti-Trop 2 antibodies have been generated, they did not present significant antitumor activities in in vivo model when used as naked antibodies without conjugation with drugs, toxins, or radioisotopes until the development of two novel anti-Trop 2 antibodies AR47A6.4.2 and Pr1E11 showing significant antitumor activity in vivo (Ikeda et al, 2016;Truong et al, 2007). With low internalization activity and high cell surface retention, those antibodies displayed potent in vivo antibody-dependent cellular cytotoxicity (ADCC) and/or complement-dependent cytotoxicity (CDC) activities in pancreatic, colon, breast, and prostate human cancer models, suggesting the potential therapeutic value of anti-Trop 2 antibodies for the treatment of solid tumors (Ikeda et al, 2015;Ikeda et al, 2016;Truong et al, 2007). However, no further data have been reported recently.…”

Section: Anti-trop 2 Antibodiesmentioning

confidence: 99%

Recent advances in trophoblast cell‐surface antigen 2 targeted therapy for solid tumors

Liao

Wang

Zeng

et al. 2021

Drug Development Research

View full text Add to dashboard Cite

Trophoblast cell-surface antigen 2 (Trop 2) is a transmembrane glycoprotein that is highly expressed in various cancer types with relatively low or no baseline expression in most normal tissues. Its overexpression is associated with tumor growth and poor prognosis; Trop 2 is, therefore, an ideal therapeutic target for epithelial cancers. Several Trop 2 targeted therapeutics have recently been developed for the treatment of cancers, such as anti-Trop 2 antibodies and antibody-drug conjugates (ADCs), as well as Trop 2-specific cell therapy. In particular, the safety and clinical benefit of Trop 2-based ADCs have been demonstrated in clinical trials across multiple tumor types, including those with limited treatment options, such as triple-negative breast cancer, platinum-resistant urothelial cancer, and heavily pretreated non-small cell lung cancer. In this review, we elaborate on recent advances in Trop 2 targeted modalities and provide an overview of novel insights for future developments in this field.

show abstract

“…Although several anti-Trop 2 antibodies have been generated, they did not present significant antitumor activities in in vivo model when used as naked antibodies without conjugation with drugs, toxins or radioisotopes until the development of two novel anti-Trop 2 antibodies AR47A6.4.2 and Pr1E11 showing significant antitumor activity in vivo [54,55]. With low internalization activity and high cell surface retention, those antibodies displayed potent in vivo antibody-dependent cellular cytotoxicity (ADCC) and/or complement-dependent cytotoxicity (CDC) activities in pancreatic, colon, breast and prostate human cancer models, suggesting the potential therapeutic value of anti-Trop 2 antibodies for the treatment of solid tumors [54][55][56]. However, no further data have been reported recently.…”

Section: Trop 2 Targeted Therapy 51 Anti-trop 2 Antibodiesmentioning

confidence: 99%

Recent Advances in Trop 2 Targeted Therapy for Solid Tumors

Liao¹,

Wang²,

Zeng³

et al. 2020

Preprint

View full text Add to dashboard Cite

Trophoblast cell-surface antigen 2 (Trop 2) is a transmembrane glycoprotein that is highly expressed in various cancer types with relatively low or no baseline expression in most of normal tissues. Its overexpression is associated with tumor growth and poor prognosis; Trop 2 is therefore, an ideal therapeutic target for epithelial cancers. Several Trop 2 targeted therapeutics have recently been developed for the treatment of cancers, such as anti-Trop 2 antibodies and antibody-drug conjugates (ADCs), as well as Trop 2-specific cell therapy. In particular, the safety and clinical benefit of Trop 2-based ADCs have been demonstrated in clinical trials across multiple tumor types, including those with limited treatment options, such as triple-negative breast cancer, platinum-resistant urothelial cancer, and heavily pretreated non-small cell lung cancer. In this review, we elaborate on recent advances in Trop 2 targeted modalities and provide an overview of novel insights for future developments in this field.

show abstract

Pr1E11, a novel anti-TROP-2 antibody isolated by adenovirus-based antibody screening, recognizes a unique epitope

Cited by 19 publications

References 18 publications

<p>Targeting Trop-2 in solid tumors: future prospects</p>

<p>Targeting Trop-2 in solid tumors: future prospects</p>

Recent advances in trophoblast cell‐surface antigen 2 targeted therapy for solid tumors

Recent Advances in Trop 2 Targeted Therapy for Solid Tumors

Contact Info

Product

Resources

About